Texas' top court nixes $32M Vioxx award

Merck ($MRK) won a reversal of the $32 million jury verdict in a Texas case over the Vioxx painkiller. The state's Supreme Court decided that the family of Leonel Garza didn't produce enough evidence to show Vioxx caused his heart attack, thus tossing out the 2006 verdict. Report

Suggested Articles

In a trial called Empacta, Roche's IL-6 inhibitor cut ventilator use, but didn't significantly cut the risk of death in COVID-19 pneumonia patients.

Officials in New York charged Johnson & Johnson with violating insurance laws with its opioid marketing.

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.